CASI Pharmaceuticals (CASIF) Gains from Investment Securities (2022 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Gains from Investment Securities came in at -$21000.0 in Q3 2025, down 101.68% YoY from $1.3 million in Q3 2024, and down 118.92% on a QoQ basis from $111000.0 in Q2 2025.
CASI Pharmaceuticals (CASIF) Gains from Investment Securities (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 4 years of Gains from Investment Securities data on file, last reported at -$21000.0 in Q3 2025.
- Quarterly Gains from Investment Securities fell 101.68% year-over-year to -$21000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$1.1 million (down 151.33% YoY) and the FY2024 annual result came in at $479000.0, changed N/A from the prior year.
- Gains from Investment Securities fell to -$21000.0 in Q3 2025, from $111000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $1.9 million in Q2 2024 to a low of -$2.5 million in Q4 2024.
- A 4-year average of -$198833.3 and a median of -$33500.0 in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities soared 12410.0% — and 2025, when it plunged 101.68%.
- Tracing CASIF's Gains from Investment Securities over 4 years: stood at -$46000.0 in 2022, then jumped by 121.74% to $10000.0 in 2023, then plunged by 24720.0% to -$2.5 million in 2024, then soared by 99.15% to -$21000.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$21000.0 (Q3 2025), $111000.0 (Q2 2025), and -$2.5 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -21,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Dec 31, 2024 | -2.46 Mn |
| Dec 31, 2024 | -2.46 Mn |
| Sep 30, 2024 | 1.25 Mn |
| Sep 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | 1.86 Mn |
| Sep 30, 2023 | 10,000.00 |
| Sep 30, 2023 | 10,000.00 |
| Jun 30, 2023 | -938,000.00 |
| Jun 30, 2023 | -938,000.00 |
| Mar 31, 2023 | -140,000.00 |
| Mar 31, 2023 | -140,000.00 |
| Dec 31, 2022 | -46,000.00 |
| Dec 31, 2022 | -46,000.00 |
| Sep 30, 2022 | 696,000.00 |
| Sep 30, 2022 | 696,000.00 |